Philip is a physician scientist and cancer biologist with expertise in clinical pathways, drug development and biomarker discovery.

Philip joined Step Pharma in June 2021 and was promoted from Vice President, Head of Research & Translation Medicine to Chief Scientific Officer in January 2021. Prior to this, he held senior leadership roles in biotech and biopharma companies, overseeing oncology drug development and biomarker discovery programmes. He is a cofounder of Gabriel Precision Oncology, a clinical software company also focussed on improving outcomes for those living with cancer. Philip is a board-certified haematologist with over 16 years frontline healthcare experience as well as biopharmaceutical industry experience, particularly in translational medicine, drug development, and biomarker discovery.

Philip is a Member of the Royal College of Physicians, UK, and a Fellow of the Royal College of Pathologists, UK. He holds a PhD in molecular cancer biology from the University of Cambridge, UK. Following this he conducted post-doctoral research studies at the BC Cancer Agency, Vancouver, Canada, and has more than 100 peer-reviewed publications. Philip is an Honorary Professor of Translational Medical at the Hull York Medical School, UK.


Step Pharma is led by a highly motivated management team and an exceptional syndicate of international investors, all driven to bring about a step change in cancer treatment for patients.